Excess primary intestinal lymphoproliferative disorders in patients with inflammatory bowel disease

Author： Sokol Harry   Beaugerie Laurent   Maynadié Marc   Laharie David   Dupas Jean-Louis   Flourié Bernard   Lerebours Eric   Peyrin-Biroulet Laurent   Allez Matthieu   Simon Tabassome   Carrat Fabrice   Brousse Nicole    

Publisher： Blackwell Publishing

ISSN： 1078-0998

Source： Inflammatory Bowel Diseases, Vol.18, Iss.11, 2012-11, pp. : 2063-2071

Disclaimer: Any content in publications that violate the sovereignty, the constitution or regulations of the PRC is not accepted or approved by CNPIEC.

Previous Menu Next

Abstract

Related content

Role of probiotics in inflammatory bowel disease and intestinal infections

By Campieri M   Venturi A   Gionchetti P   Rizzello F   Amadini C   Palmonari V   Romagnoli R   Simone C De  

Expert Opinion on Therapeutic Patents, Vol. 11, Iss. 8, 2001-08 ,pp. : 1277-1283

Informa Healthcare

Access to resources Recommend Favorite

Modification of Intestinal Flora in the Treatment of Inflammatory Bowel Disease

By  

Current Pharmaceutical Design, Vol. 9, Iss. 4, 2003-02 ,pp. : 333-346

Bentham Science Publishers

Access to resources Recommend Favorite

Pharmacokinetics of Cyclosporin Microemulsion in Patients with Inflammatory Bowel Disease

By Latteri M.  

Clinical Pharmacokinetics, Vol. 40, Iss. 6, 2001-01 ,pp. : 473-483

Adis International

Access to resources Recommend Favorite

Pharmacogenetics of Therapy in Inflammatory Bowel Disease Patients

By  

Current Pharmacogenomics, Vol. 5, Iss. 3, 2007-09 ,pp. : 235-247

Bentham Science Publishers

Access to resources Recommend Favorite

Inadequate sunlight exposure in patients with inflammatory bowel disease

By  

Journal of Digestive Diseases, Vol. 19, Iss. 1, 2018-01 ,pp. : 8-14

John Wiley & Sons Inc

Access to resources Recommend Favorite